# Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

> **NCT07311746** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (estimated)

## Conditions studied

- T-cell Prolymphocytic Leukemia
- Refractory T-Cell Prolymphocytic Leukemia

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Cladribine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07311746
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2029-01-31
- **Final completion:** 2031-01-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311746, "Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07311746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*